Delivery Order SPE2DB24D2205-SPE2DB25FEDHW
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $24,960.51 with firm fixed pricing. This competitively awarded, non-set-aside contract is scheduled for completion by September 15, 2025, with performance of work occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $6,845.09 under a firm fixed-price contract. This competitively awarded, non-set-aside delivery order is scheduled for completion by June 3, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,549.80 on July 29, 2025, for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 30, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $1,232.98 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 16, 2025, for the supply of Multaq (dronedarone) 400 mg tablets in a quantity of 60 units. The contract, which is not set-aside, has an ultimate completion date of May 19, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under a larger indefinite delivery vehicle that...
- The Defense Logistics Agency awarded a $6,030.23 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Multaq 400 mg tablets (60-count units). This firm fixed-price contract, which is a child order under a larger vehicle, represents a competitive award with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order draws...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $1,959.09. This firm fixed-price delivery order, with an ultimate completion date of May 13, 2025, represents a non-competitive procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor will fulfill this order from its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $11,602.70. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on April 25, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under the vendor's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency Medical Supply Chain awarded a $57,770.08 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Multaq 400 mg tablets (60-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 4, 2025, with performance based in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal military and veteran...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $8,201.13. This firm fixed-price delivery order, which is scheduled for completion by August 19, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) valued at $3,359.77, with an ultimate completion date of September 11, 2025. This competitive award, issued September 10, 2025, utilizes firm fixed-price pricing with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a...
- SPE2DB24D2205Indefinite Delivery Contract
- SPE2DB24D2205-SPE2DB25FEDHWDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Multaq 400 mg tablets (60-count) valued at $9,625.47 under a firm fixed-price contract. This non-set-aside award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, supplying brand-name and generic medications, vaccines, and medical devices to military and veteran healthcare systems. This delivery order fulfills pharmaceutical supply needs for the Defense Health Agency and other federal healthcare customers through AmerisourceBergen's competitively awarded prime vendor contract. The award demonstrates the contractor's continued role as a major supplier within the DLA Medical Supply Chain, which maintains inventory across multiple therapeutic domains to support military healthcare programs globally. Multaq (dronedarone) is an antiarrhythmic medication used in cardiac care, reflecting the breadth of therapeutic categories covered under the company's federal pharmaceutical distribution mandate. The ultimate completion date is June 6, 2025, with place of performance in Conshohocken, Pennsylvania.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.6k | 6/5/25 |